Pacira 2025 preliminary revenue slightly misses expectations

Overview

• Non-opioid pain therapy firm's preliminary 2025 revenue slightly missed analyst expectations

• EXPAREL sales volume grew 7% in Q4, marking strongest performance in three years

• Company repurchased 2 mln shares for $50 mln in Q4

Outlook

• Company did not provide specific financial guidance for 2026

Result Drivers

• EXPARAL VOLUME GROWTH - Fourth qtr EXPAREL sales driven by 7% volume growth, despite vial mix shift and discounting from new GPO partnership

• STABLE ZILRETTA SALES - Fourth qtr ZILRETTA sales remained stable at $33 mln compared to $33.1 mln in 2024

• IOVERA SALES INCREASE - Fourth qtr iovera° sales increased to $7 mln from $6.5 mln in 2024

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Pacira Biosciences Inc is $28.00, about 7.7% above its January 7 closing price of $26.00

• The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nGNX2T04GM

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)